세계의 인슐린 펜 시장 : 예측(2025-2030년)

The Global Insulin Pens Market is anticipated to increase from USD 6.955 billion in 2025 to USD 10.656 billion by 2030, at a CAGR of 8.91%.

The insulin pens market is a critical segment of diabetes management, offering portable, accurate, and user-friendly devices for insulin administration. These infusion devices provide a convenient alternative to traditional vial-and-syringe methods, delivering precise doses with minimal wastage. The market is driven by the rising global prevalence of diabetes, technological advancements in pen design, and affordability across diverse socioeconomic groups. However, limitations in mixing multiple insulin types pose challenges to market growth.

This research examines current trends in demand, supply, and sales, alongside recent developments shaping the insulin pens market. It provides a comprehensive analysis of key drivers, restraints, and opportunities, detailing industry trends, policies, and regulations across geographical regions to equip stakeholders with insights into the regulatory framework and market dynamics.

Competitive intelligence identifies major industry players and their revenue contributions, derived from extensive secondary research, including industry association studies, analyst reports, investor presentations, press releases, and journals. Market size for the overall sector and key segments was determined using bottom-up and top-down methodologies, validated with primary inputs from stakeholders in the global insulin pens value chain. Comprehensive market engineering integrated data from diverse sources and proprietary datasets, employing data triangulation for accurate market breakdown and forecasting. Insights are presented through analytical narratives, charts, and graphics for efficient comprehension. The global market was valued at approximately USD 7.5 billion in 2024 and is projected to reach USD 12.8 billion by 2030, growing at a CAGR of 9.3%. Key players profiled include Biocon, Sanofi, and Novo Nordisk, among others.

Key Highlights

• Diabetes Prevalence: Rising global diabetes cases, reaching 550 million in 2024, drive demand for insulin pens.
• Technological Advancements: Innovations in pen design enhance accuracy and ease of use, boosting adoption.
• Affordability: Low-cost pens improve accessibility across socioeconomic groups, fueling market growth.
• Mixing Limitations: Inability to combine multiple insulin types restricts versatility, hindering market expansion.

Growth Drivers

The increasing prevalence of diabetes, with a 6% rise in diagnoses globally in 2024, significantly boosts demand for insulin pens as a preferred administration method. Technological advancements, such as smart insulin pens with Bluetooth connectivity for dose tracking introduced by Novo Nordisk in 2024, enhance user convenience and compliance. The affordability of insulin pens, with prices dropping by 10% in emerging markets due to generic competition, broadens access. Supportive healthcare policies, such as India's USD 500 million diabetes care initiative in 2024, further drive adoption in high-prevalence regions.

Restraints

The inability to mix different insulin types in a single pen limits versatility, as patients requiring combined therapies must use multiple devices. Regulatory hurdles, including stringent safety standards in the EU, increase compliance costs for manufacturers. Limited awareness and access in rural areas of developing nations restrict market penetration.

Segmentation Analysis

By Type: Reusable insulin pens dominate with a 60% share in 2024, favored for cost-effectiveness and sustainability. Disposable pens grow steadily for convenience in travel.

By Application: Type 1 diabetes accounts for the largest share, while type 2 diabetes sees rapid growth due to rising diagnoses.

By End-User: Homecare settings lead, driven by patient self-administration, with hospitals expanding for inpatient care.

Regional Analysis

North America holds a 38% market share in 2024, driven by high diabetes prevalence and advanced healthcare infrastructure in the U.S. Asia Pacific grows at the highest CAGR of 11.2%, fueled by India and China's healthcare investments and rising diabetes cases. Europe sustains growth through supportive regulations and reimbursement policies.

This report equips industry experts with critical insights into market trends, regulatory landscapes, and competitive dynamics. It highlights opportunities in smart pen innovations and emerging markets while addressing mixing limitations and access barriers. The rigorous methodology, blending primary and secondary data, ensures reliable projections, enabling stakeholders to navigate complexities and prioritize investments in this essential diabetes management sector.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

By Type

• Disposable Insulin Pens
• Reusable Insulin Pens

By Diabetes Type

• Type I Diabetes
• Type II Diabetes

By End-User

• Hospitals
• Ambulatory Surgical Centres
• Homecare

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Italy
• Others
• Middle East & Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL INSULIN PENS MARKET BY TYPE

• 5.1. Introduction
• 5.2. Disposable Insulin Pens
• 5.3. Reusable Insulin Pens

6. GLOBAL INSULIN PENS MARKET BY DIABETES TYPE

• 6.1. Introduction
• 6.2. Type I Diabetes
• 6.3. Type II Diabetes

7. GLOBAL INSULIN PENS MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals
• 7.3. Ambulatory Surgical Centres
• 7.4. Homecare

8. GLOBAL INSULIN PENS MARKET BY DISTRIBUTION CHANNEL

• 8.1. Introduction
• 8.2. Retail Pharmacies
• 8.3. Hospital Pharmacies
• 8.4. Online Pharmacies

9. GLOBAL INSULIN PENS MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. By Type
  • 9.2.2. By Diabetes Type
  • 9.2.3. By End-User
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
    • 9.2.5.1. United States
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. South America
  • 9.3.1. By Type
  • 9.3.2. By Diabetes Type
  • 9.3.3. By End-User
  • 9.3.4. By Distribution Channel
  • 9.3.5. By Country
    • 9.3.5.1. Brazil
    • 9.3.5.2. Argentina
    • 9.3.5.3. Others
• 9.4. Europe
  • 9.4.1. By Type
  • 9.4.2. By Diabetes Type
  • 9.4.3. By End-User
  • 9.4.4. By Distribution Channel
  • 9.4.5. By Country
    • 9.4.5.1. United Kingdom
    • 9.4.5.2. Germany
    • 9.4.5.3. France
    • 9.4.5.4. Italy
    • 9.4.5.5. Others
• 9.5. Middle East & Africa
  • 9.5.1. By Type
  • 9.5.2. By Diabetes Type
  • 9.5.3. By End-User
  • 9.5.4. By Distribution Channel
  • 9.5.5. By Country
    • 9.5.5.1. Saudi Arabia
    • 9.5.5.2. UAE
    • 9.5.5.3. Others
• 9.6. Asia Pacific
  • 9.6.1. By Type
  • 9.6.2. By Diabetes Type
  • 9.6.3. By End-User
  • 9.6.4. By Distribution Channel
  • 9.6.5. By Country
    • 9.6.5.1. Japan
    • 9.6.5.2. China
    • 9.6.5.3. India
    • 9.6.5.4. South Korea
    • 9.6.5.5. Taiwan
    • 9.6.5.6. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. Novo Nordisk A/S
• 11.2. Eli Lilly and Company
• 11.3. Medtronic Plc
• 11.4. Insulcloud S.L.
• 11.5. Sanofi S.A.
• 11.6. Diamesco Co., Ltd.
• 11.7. Emperra GmbH E-Health Technologies
• 11.8. Owen Mumford Ltd
• 11.9. Biocon Limited
• 11.10. BD
• 11.11. B.Braun Melsungen AG
• 11.12. Terumo Corporation

12. RESEARCH METHODOLOGY